Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30222931 | 0.83 | — | — | |
| SCHEMBL30913963 | 0.80 | CCR2 (0.49) | NAAAMEN1KMT2A | |
| SCHEMBL24690554 | 0.79 | — | — | |
| SCHEMBL23883277 | 0.78 | CTSL (0.50) | CTSLCTSB | |
| SCHEMBL23883282 | 0.78 | CTSL (0.50) | CTSLCTSB | |
| SCHEMBL23883281 | 0.78 | CTSL (0.50) | CTSLCTSB | |
| SCHEMBL19924782 | 0.77 | CTSL (0.36) | CTSLCTSB | |
| SCHEMBL6064485 | 0.77 | CTSL (0.36) | CTSLCTSB | |
| SCHEMBL7417089 | 0.77 | CTSL (0.36) | CTSLCTSB | |
| SCHEMBL30913978 | 0.76 | CTSL (0.49) | CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023014758-A1 | INHIBITORS FOR CORONAVIRUSES | COCRYSTAL PHARMA, INC. (US) | 2023-02-09 | — | — | WO | disclosed |